So your position is that the presentation given by Mulholland on day 2 of the Frontiers in Cancer Immunotherapy conference of the New York Academy of Sciences in May 2022 was not a science conference?
No it was not, the NWBO presentation was to present TLD which is most and foremost for investors not so much for MD's and other scientists. If the NWBO presentation was to entice the science community then LP would not have tried to halt the stock from trading which Finra/OTC refused.